DNA methylation, inflammatory microenvironments, reactive oxygen species, and signal transducer and activator of transcription 3 (STAT3) activation are known to contribute to the mesenchymal trans-differentiation of GBM [14]. The gene discussed is STAT3; the disease is glioblastoma.